Panthera Vax, LLC

Panthera Vax, LLC is a biotechnology company focused on designing solutions to enhance human and animal health. The firm specializes in the development of practical and scalable vaccines, as well as novel vaccine delivery methods. Its technical approach includes the proprietary DIRECT (Defined Immune-Relevant Epitope Combination and Targeting) technology, which involves defining immune-relevant epitopes and developing targeted delivery systems to elicit specific immune responses. Additionally, the company is engaged in screening and engineering small-molecule inhibitors, probiotics, and antibodies to address critical microbial and viral pathogens.

Beyond vaccine development, the company provides antibody-related services, including a streamlined pipeline for therapeutic humanized-antibody development. Its comprehensive approach encompasses peptide design, ScFv screening, in-vitro evolution, humanization, and rigorous functional testing to ensure efficacy. The company emphasizes strict confidentiality and ethical standards in managing client data and intellectual property, positioning itself as a partner for industries seeking to advance therapeutic targets and diagnostic capabilities.